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A healthy 68-year-old man presented in the emer-
gency room with a sudden episode of headache
and vomiting together with disequilibrium and
crural paresis. The laboratory evaluation revealed
hyponatraemia (Na+115 mEq/L). Head MRI
demonstrated a giant 40×25×31 mm pituitary
lesion (ﬁgures 1 and 2). Laboratory studies revealed
growth hormone (GH) 0.1 ng/mL (0.06–5),
follicle-stimulating hormone (FSH) 14.5 mUI/mL
(0.7–11.1), luteinising hormone (LH) 1.9 mUI/mL
(0.8–7.6), prolactin 23.1 ng/mL (2.5–17), low free
thyroxine (fT4) 0.4 ng/mL (0.8–1.9), thyroid-
stimulating hormone (TSH) 7.88 mUI/mL (0.4–4),
cortisol 2.4 μg/dL (5–25), adrenocorticotropic
hormone (ACTH) 9.26 pg/mL (<46), insulin-like
growth factor-1 (IGF1) <25 ng/mL (69–200), tes-
tosterone <0.04 ng/mL (5.6–19) and sex hormone
binding globulin (SHBG) 30 nmol/L (13–71).
The cerebral lesion was surgically removed by a
trans-sphenoidal approach and the histopathological
evaluation has revealed pituitary adenoma (PA)
producing gonadotropic hormones (ﬁgures 3–5).
Currently, the patient is completely recovered. At
the third month postsurgery, laboratory studies
revealed GH, FSH, LH, cortisol, ACTH, IGF1, tes-
tosterone and SHBG were normal; TSH 4.3 mUI/
mL, fT4 0.6 ng/mL.
The patient is currently under medical treatment
with levothyroxine (100 mg/day) without other hor-
monal replacement therapies. Also, due to the risk
of removing normal functioning pituitary tissue, he
was started on corticosteroid treatment in the pre-
operative period during the ﬁrst month.
A subsequent head MRI is scheduled for the
sixth postsurgical month, to assess any eventual
residual adenoma.
The PA is a benign tumour diagnosed in 15–20
million individuals a year. It is responsible for
10–15% of intracranial tumours. PA is classiﬁed as
a macroadenoma if it has a diameter of ≥10 mm
and as a giant adenoma if the diameter is ≥40 mm.
Symptoms depend on the size, mass effect and hor-
monal dysfunction.1
Gonadotropic adenomas comprise 10% of PAs
and are generally deﬁned as non-functioning aden-
omas. Symptoms and signs are usually related with
mass effect requiring high clinical suspicion for an
early diagnose. The most common symptom is
impaired vision (caused by compression of optic
chiasm). However, its onset is gradual. In this par-
ticular case, despite the size of the adenoma and
compression of the optic chiasm, the patient did
not have any visual deﬁcit.
In some cases, as in ours, endocrine testing
reveals hyperprolactinaemia,2 which is due to com-
pression of the pituitary stalk. The majority of the
cases present hypopituitarism caused by the com-
pression of normal pituitary cells. Generally, the
levels of gonadotropins are low, ending up in
Figure 1 MRI Sagittal T1-weighted image showing a
sellar and suprasellar tumour, remodelling the sella
turcica. Note the extension of the tumour to the
sphenoid sinus.
Figure 2 MRI Coronal T2-weighted image illustrates
the heterogeneous MR signal evolution. Note the mass
effect and compression over the optic chiasm and the
deviation of the vascular arcade (both A1 segments of
the anterior cerebral arteries and anterior communicating
artery).
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clinical hypogonadism. In this particular case the initial study
has revealed low levels of testosterone. Nevertheless, the patient
did not report about any decreased libido or erectile dysfunc-
tion. His testosterone levels have returned to normal value after
surgery.
The most sensitive image method for evaluating pituitary
tumours is MRI. It allow clinicians to distinguish PAs from
other conditions such as craniopharyngiomas or meningiomas.3
Surgery remains the primary option and the trans-sphenoidal
approach method is the most popular technique. Radiation
therapy (RT) is useful to prevent the regrowth of residual
adenomas following trans-sphenoidal surgery. The decision to
initiate RT depends on the amount and localisation of residual
tissue.1 3
Whatever treatment is used, lifetime re-evaluation by endo-
crinology and neurosurgery is needed due to the risk of
recurrence.
Learning points
▸ Lesion mass effect and hormonal dysfunction determine the
initial presentation of pituitary macroadenomas.
▸ Surgery remains the treatment of choice.
▸ Histopathological study with immunostaining is important to
conﬁrm the diagnosis and to deﬁne medical therapy.
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Figure 3 Histology of the pituitary adenoma. Tumour with solid and
diffuse pattern, consisting of monomorphic, round and cohesive cells
without atypia or mitotic activity (H&E stain).
Figure 4 Pituitary adenoma with immunoreactivity for
follicle-stimulating hormone (FSH) (FSH-immunohistochemistry stain).
Figure 5 Pituitary adenoma with immunoreactivity for luteinising
hormone (LH) (LH-immunohistochemistry stain).
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